The coronavirus 2019 (COVID-19) pandemic has caused significant mortality around the world and the focus has been on reducing the number of infections. In order not to compromise treatment of oncology patients, reducing the number of patients with COVID-19 undergoing treatment is mandatory. We reviewed the experience of the National Institute of Cancer in Milan and compared it with our experience.
Johns Hopkins University & Medicine. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins, https://coronavirus.jhu.edu/map.html (2020, accessed 2 April 2020).
2.
SiegelRLMillerKDJemalA. Cancer statistics, 2017. CA Cancer J Clin2017; 67: 7–30.
3.
SandersJMMonogueMLJodlowskiTZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA2020; 2019: E1–E13.
4.
RomanovBK. Coronavirus disease COVID-2019. Saf Risk Pharmacother2020; 8: 3–8.
5.
ShiHHanXJiangN, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis2020; 20: 425–434.
6.
ValenzaFPapagniGMarchianòA, et al. Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano. Tumori20203: 193–202.
7.
BilkhuRVivianoASafticI, et al. COVID-19: chest drains with air leak: the silent ‘super spreader’?CTSNet Epub 2020 Apr 8.
